Publications
Inhibition of Complement Factor C5a or C5aR for Cholesterol Crystal Embolism-Related Vascular Thrombosis with Microvascular Injury and Its Consequences.Zhao, D.; Han, C.; Mammadova-Bach, E.; Watanabe-Kusunoki, K.; Honda, T. S. B.; Li, Y.; Li, C.; Li, Q.; Long, H.; Lyubenov, L.; Shi, C.; Santovito, D.; Weber, C.; Boor, P.; Droste, P.; Parikh, S.; Shapiro, J.; Chiara, L. D.; Carangelo, G.; Romagnani, P.; Klussmann, S.; Vater, A.; Anders, H.-J.
2024 Kidney International
|
Gasdermin D drives focal Crystalline Thrombotic Microangiopathy by accelerating Immunothrombosis and NecroinflammationWatanabe-Kusunoki, K.; Li, C.; Bandeira Honda, T. S.; Zhao, D.; Kusunoki, Y.; Ku, J.; Long, H.; Klaus, M.; Han, C.; Braun, A.; Mammadova-Bach, E.; Linkermann, A.; Van Avondt, K.; Richter, M.; Soehnlein, O.; Linder, M. I.; Klein, C.; Steiger, S.; Anders, H.-J.
2024 Blood
|
Finerenone Added to RAS/SGLT2 Blockade for Chronic Kidney Disease in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3-/- Mice.Zhu, Z.; Rosenkranz, K. A.; Kusunoki, Y.; Li, C.; Klaus, M.; Gross, O.; Angelotti, M.-L.; Antonelli, G.; Cirillo, L.; Romagnani, P.; Bouteldja, N.; Sadr, A. V.; Bülow, R. D.; Boor, P.; Anders, H.-J.
2023 J Am Soc Nephrol
|
Asymptomatic Hyperuricaemia in Chronic Kidney Disease: Mechanisms and Clinical Implications. |
The Five Types of Glomerulonephritis Classified by Pathogenesis, Activity, and Chronicity (GN-AC)Romagnani, P.; Kitching, A. R.; Leung, N.; Anders, H.-J.
2023 Nephrol Dial Transplant
|
Neutrophil circadian rhythm is associated with different outcomes of acute kidney injury due to cholesterol crystal embolismShi, C.; Zhao, D.; Lyubenov, L.; Motrapu, M.; Li, N.; Steiger, S.; Mammadova-Bach, E.; Yang, L.; Liu, D.; Anders, H.-J.
2022 Frontiers in Cardiovascular Medicine
|